Other Events ·
Opus Genetics, Inc. issued a revised data presentation on September 11, 2026, correcting an immaterial error in…
IRDOpus Genetics, Inc.
Opus Genetics, Inc. issued a revised data presentation on September 11, 2026, correcting an immaterial error in translating logMAR visual acuity to ETDRS letters for Cohort 1 of its Phase 1/2 trial of OPGx-BEST1 in patients with BEST1-related retinal diseases. The correction adjusted mean best-corrected visual acuity changes from baseline through three months, showing individual participant improvements or losses ranging from a 12-letter gain to an 8-letter loss in treated eyes. High-resolution microperimetry images were added to the appendix. Opus Genetics operates in the biotechnology industry and develops gene therapies for inherited retinal diseases.